What happens if I overdose Tranexamic Acid?
Contact 1-800-222-1222 (the American Association of Poison Control Centers), your local ( ), or emergency room immediately. Symptoms may include dizziness on standing; lightheadedness; severe nausea or vomiting.
Proper storage of Tranexamic Acid tablet:
Store Tranexamic Acid tablet at 77 degrees F (25 degrees C). Brief storage at temperatures between 59 and 86 degrees F (15 and 30 degrees C) is permitted. Store away from heat, moisture, and light. Do not store in the bathroom. Keep Tranexamic Acid tablet out of the reach of children and away from pets.
Overdose of Tranexamic Acid in details
There are no known cases of intentional overdose with Tranexamic Acid Tablets and no subjects in the clinical program took more than 2 times the prescribed amount of Tranexamic Acid Tablets in a 24-hour period (>7800 mg/day). However, cases of overdose of Tranexamic Acid have been reported. Based on these reports, symptoms of overdose may include gastrointestinal (nausea, vomiting, diarrhea); hypotensive (e.g., orthostatic symptoms); thromboembolic (arterial, venous, embolic); visual impairment; mental status changes; myoclonus; or rash. No specific information is available on the treatment of overdose with Tranexamic Acid Tablets. In the event of overdose, employ the usual supportive measures (e.g., clinical monitoring and supportive therapy) as dictated by the patient's clinical status.
What should I avoid while taking Tranexamic Acid?
This medication may impair your vision. Be careful if you drive or do anything that requires you to be able to see clearly.
Tranexamic Acid warnings
Thromboembolic Risk
Concomitant Use of Hormonal Contraceptives
Combination hormonal contraceptives are known to increase the risk of venous thromboembolism, as well as arterial thromboses such as stroke and myocardial infarction. Because Tranexamic Acid Tablets are antifibrinolytic, the risk of venous thromboembolism, as well as arterial thromboses such as stroke, may increase further when hormonal contraceptives are administered with Tranexamic Acid Tablets. This is of particular concern in women who are obese or smoke cigarettes, especially smokers over 35 years of age.
Women using hormonal contraception were excluded from the clinical trials supporting the safety and efficacy of Tranexamic Acid Tablets, and there are no clinical trial data on the risk of thrombotic events with the concomitant use of Tranexamic Acid Tablets with hormonal contraceptives. However, there have been US postmarketing reports of venous and arterial thrombotic events in women who have used Tranexamic Acid Tablets concomitantly with combination hormonal contraceptives. For this reason, concomitant use of Tranexamic Acid with combination hormonal contraceptives is contraindicated..
Factor IX Complex Concentrates or Anti-Inhibitor Coagulant Concentrates
Tranexamic Acid Tablets are not recommended for women taking either Factor IX complex concentrates or anti-inhibitor coagulant concentrates because the risk of thrombosis may be increased.
All-Trans Retinoic Acid (Oral Tretinoin)
Exercise caution when prescribing Tranexamic Acid Tablets to women with acute promyelocytic leukemia taking all-trans retinoic acid for remission induction because of possible exacerbation of the procoagulant effect of all-trans retinoic acid.
Ocular Effects
Retinal venous and arterial occlusion has been reported in patients using Tranexamic Acid. Patients should be instructed to report visual and ocular symptoms promptly. In the event of such symptoms, patients should be instructed to discontinue Tranexamic Acid Tablets immediately and should be referred to an ophthalmologist for a complete ophthalmic evaluation, including dilated retinal examination, to exclude the possibility of retinal venous or arterial occlusion.
Severe Allergic Reaction
A case of severe allergic reaction to Tranexamic Acid Tablets was reported in the clinical trials, involving a subject who experienced dyspnea, tightening of her throat, and facial flushing that required emergency medical treatment. A case of anaphylactic shock has also been reported in the literature, involving a patient who received an intravenous bolus of Tranexamic Acid.
Subarachnoid Hemorrhage
Cerebral edema and cerebral infarction may be caused by use of Tranexamic Acid Tablets in women with subarachnoid hemorrhage.
Ligneous Conjunctivitis
Ligneous conjunctivitis has been reported in patients taking Tranexamic Acid. The conjunctivitis resolved following cessation of the drug.
What should I discuss with my healthcare provider before taking Tranexamic Acid?
Some medical conditions may interact with Tranexamic Acid tablet. Tell your doctor or pharmacist if you have any medical conditions, especially if any of the following apply to you:
- if you are pregnant, planning to become pregnant, or are breast-feeding
- if you are taking any prescription or nonprescription medicine, herbal preparation, or dietary supplement
- if you have allergies to medicines, foods, or other substances
- if you have kidney disease, upper respiratory tract bleeding, certain blood problems (disseminated intravascular coagulation [DIC]), or a history of blood clots
Some MEDICINES MAY INTERACT with Tranexamic Acid tablet. Tell your health care provider if you are taking any other medicines, especially any of the following:
- Anti-inhibitor coagulant concentrates, factor IX complex concentrates, or tretinoin because risk of blood clots may be increased
This may not be a complete list of all interactions that may occur. Ask your health care provider if Tranexamic Acid tablet may interact with other medicines that you take. Check with your health care provider before you start, stop, or change the dose of any medicine.
Tranexamic Acid precautions
Patients with irregular menstrual bleeding should not use Tranexamic Acid until the cause of the irregularity has been established. If menstrual bleeding is not adequately reduced by Tranexamic Acid, an alternative treatment should be considered.
Patients with a high risk for thrombosis (a previous thromboembolic event and a family history of thromboembolic disease) should use Tranexamic Acid only if there is a strong medical indication and under strict medical supervision.
Patients with disseminated intravascular coagulation, who require treatment with Tranexamic Acid, must be under the strict supervision of a physician experienced in treating this disorder.
The blood levels are increased in patients with renal insufficiency. Therefore, a dose reduction is recommended, see Dosage & Administration.
In haematuria from the upper urinary tract blood clots can, in a few cases, lead to ureteric obstruction.
Convulsions have been reported in association with Tranexamic Acid treatment.
Effects on the Ability to Drive or Operate Machinery: Tranexamic Acid may cause dizziness and therefore, may influence the ability to drive or use machines.
Impairment of Fertility: There are no clinical data in humans supporting the impact of Tranexamic Acid on fertility. Fertility was not affected in male or female rats at high oral doses up to approximately 850-880 mg/kg/day.
Use in pregnancy: Tranexamic Acid crosses the placenta and appears in cord blood at concentrations approximately equal to maternal concentration. Clinical experience of use in pregnant women is limited. Animal studies have not supplied any evidence of an increased incidence of foetal damage.
Use in lactation: Tranexamic Acid is excreted into breast milk.
Use in children: Clinical experience with Tranexamic Acid in menorrhagic children <15 years is not available.
What happens if I miss a dose of Tranexamic Acid?
Call your doctor for instructions if you miss a dose.
References
- DailyMed. "TRANEXAMIC ACID: DailyMed provides trustworthy information about marketed drugs in the United States. DailyMed is the official provider of FDA label information (package inserts).". https://dailymed.nlm.nih.gov/dailyme... (accessed September 17, 2018).
- DrugBank. "tranexamic acid". http://www.drugbank.ca/drugs/DB00302 (accessed September 17, 2018).
- MeSH. "Antifibrinolytic Agents". https://www.ncbi.nlm.nih.gov/mesh/68... (accessed September 17, 2018).
Reviews
Consumer reviews
There are no reviews yet. Be the first to write one! |
Information checked by Dr. Sachin Kumar, MD Pharmacology
